RESEARCH TRIANGLE PARK, NC–CivaTech Oncology, Inc., an early stage company developing a novel medical device for the treatment of prostate cancer, has raised $800,000 in an oversubscribed private financing.

The company focuses on low-dose-rate brachytherapy, a type of radiation treatment for cancer utilizing implanted radioactive sources to kill tumor cells. At present, this type of brachytherapy is used predominantly for prostate cancer and makes use of so-called “seeds,” which are implanted in a minimally invasive surgical procedure.

CivaTech Oncology’s new device is more akin to a “radioactive string” that will replace the individual seeds and should provide more uniform and consistent radiation delivery to patients. Brachytherapy has been shown to be as effective as surgery and external beam radiation therapy in studies of long-term patient survival.

The company has been issued a U.S. patent and has other pending.

The Company was founded in 2006 by Robert and Claudia Black (two of the founders of Sicel Technologies) and Suzanne Babcock (former VP of Troxler Electronics) and is headquartered in the Park Research Center in RTP.

Commenting on the growth in consulting and other services for medical device companies in the region, Dr. Black notes: “The Triangle is poised to ‘get on the map’ as a center for medical device excellence.

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2007, TechJournal South. All rights reserved.